Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $86.5 million.

  • Century Therapeutics' Shares Outstanding (Diluted Average) rose 207.75% to $86.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $86.5 million, marking a year-over-year increase of 207.75%. This contributed to the annual value of $78.6 million for FY2024, which is 3259.68% up from last year.
  • Century Therapeutics' Shares Outstanding (Diluted Average) amounted to $86.5 million in Q3 2025, which was up 207.75% from $86.2 million recorded in Q2 2025.
  • In the past 5 years, Century Therapeutics' Shares Outstanding (Diluted Average) ranged from a high of $86.5 million in Q3 2025 and a low of $32.4 million during Q4 2022
  • Moreover, its 4-year median value for Shares Outstanding (Diluted Average) was $59.4 million (2023), whereas its average is $67.2 million.
  • In the last 5 years, Century Therapeutics' Shares Outstanding (Diluted Average) soared by 8311.12% in 2023 and then soared by 207.75% in 2025.
  • Quarter analysis of 4 years shows Century Therapeutics' Shares Outstanding (Diluted Average) stood at $32.4 million in 2022, then soared by 83.11% to $59.3 million in 2023, then skyrocketed by 32.6% to $78.6 million in 2024, then grew by 9.94% to $86.5 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $86.5 million for Q3 2025, versus $86.2 million for Q2 2025 and $86.1 million for Q1 2025.